HER-Targeted Tyrosine-Kinase Inhibitors (original) (raw)
Article navigation
[ 
](/ocl/issue/63/Suppl. 1)
Review Articles| November 13 2002
aMedical Oncology Service, Hospital General, Universitari Vall d’Hebron, Barcelona, Spain;
Search for other works by this author on:
bInstitute for Drug Development, Cancer Therapy and Research Center, San Antonio, Tex., USA
Search for other works by this author on:
Oncology (2002) 63 (Suppl. 1): 6–16.
Abstract
Improved understanding of tumor biology has led to the identification of numerous growth factors that are involved in malignant transformation and tumor progression. Many of these factors induce cellular responses through receptors with intrinsic tyrosine kinase (TK) activity. Therefore, inhibiting receptor TK activity is a way to effectively block the tumorigenic effects that arise from these pathways. The HER family of TK receptors is overexpressed or dysregulated in many types of human cancer. As a result these receptors were identified as targets for cancer therapy. Several agents have been developed that reversibly, or irreversibly, inhibit one, two or all of the HER receptors. TarcevaTM and IressaTM are HER1-TK inhibitors that are advanced in development. Clinical data show that these agents as monotherapy have antitumor activity in patients with various types of solid tumor and are well tolerated; encouraging data are also produced when Tarceva or Iressa are combined with chemotherapeutic agents. Other dual or pan-HER, reversible or irreversible, TK inhibitors are being investigated in phase I trials. Early data show that they are generally well tolerated and have provided evidence of antitumor activity. HER-TK inhibitors are exciting agents that are likely to have a substantial impact on the way we treat patients with cancer.
References
Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–137.
Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
Wells A: EGF receptor. Int J Biochem Cell Biol 1999;31:637–643.
Redemann N, Holzmann B, von Ruden T, Wagner EF, Schlessinger J, Ullrich A: Anti oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992;12:491–498.
Pedersen MW, Meltorn M, Damstrup L, Poulsen HS: The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745–760.
Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32–40S.
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452–2467.
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267–3279.
Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, Yates R: Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297–306.
Fry DW: Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999;82:207–218.
Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838–4848.
Baselga J, Averbuch SD: ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000;60 (suppl 1):33–40.
Allen LF, Cerna C, Gomez L, Yochmowitz M, Medina L, Weitman S: Investigation of the effects of CP-358,774 (OSI-774) on various human tumor specimens taken directly from patients (abstract 384). Proc NCI-EORTC-AACR 2000.
Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774:dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739–748.
Karp DD, Silberman R, Csudae R, Wirth F, Gaynes L, Posner M, Bubley G, Koon H, Bergman M, Huang M, Schnipper LE: Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors (abstract 1499). Proc Am Soc Clin Oncol 1999;18:388a.
Finkler N, Gordon A, Crozier M, Edwards R, Figueroa J, Garcia A, Hainsworth J, Irwin D, Silberman S, Allen L, Ferrante K, Fisher D, Nadler P: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma (abstract 831). Proc Am Soc Clin Oncol 2001;20:208a.
Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001;19:3967–3975.
Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312–3322.
Senzer NN, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, Silberman S, Allen L, Ferrante K, Fisher D, Marsolais C, Nadler P: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck (abstract 6). Proc Am Soc Clin Oncol 2001;20:2a.
Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, Robbins K, Oliveira J, Lewensohn R, Schuller J, Riviere A, Arvay C, Langecker P, Jacob H, Cvitkovic E, Vokes E: Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 1998;16:1054–1059.
Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088–1095.
Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC) (abstract 1235). Proc Am Soc Clin Oncol 2001;20:310a.
Nadler P: TarcevaTM (OSI-774) clinical development: non-small cell lung cancer. Presented at the 3rd International Lung Cancer Congress, Hawaii, June 2002.
Forouzesh B, Hidalgo M, Takimoto C, de Bono J, Forero L, Beeram M, Malik S, Patnaik A, Rizzo J, Hammond LA, Schwartz G, Goetz A, Mays T, Kiene A, Norris J, Tolcher A, Rowinsky EK, Nadler P, Wood D, Zitelli A: Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel (abstract 81). Proc Am Soc Clin Oncol 2002;21:21a.
Ratain MJ, George CM, Janisch L, Kindler HL, Ryan C, Wood DL, Nadler PI, Vokes EE: Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors (abstract 2115). Proc Am Soc Clin Oncol 2002;21:76b.
Forero L, Patnaik A, Hammond LA, Tolcher A, Schwartz G, Hidalgo M, Malik S, Murphy T, Goetz A, Mays T, Kiene A, Hill M, de Bono JS, Beeram M, Forouzesh B, Hao D, Zitelli A, Woods D, Nadler P, Rowinsky EK: Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin (abstract 1908). Proc Am Soc Clin Oncol 2002;21:25b.
Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241–250.
Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459–1465.
Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye SB, Keiback DG, Harris A, Ochs J: Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: evidence of activity and good tolerability (abstract 686). Proc Am Soc Clin Oncol 2000;19:177.
Ferry D, Hammond L, Ranson M, Kris MG, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S, Rowinsky E: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1), shows evidence of good tolerability and activity: final results from a phase I study (abstract 5E). Proc Am Soc Clin Oncol 2000;19:3.
Goss G, Hirte H, Batist G, Miller WH, Stewart D, Matthews S, Seymour L: NCIC CTG IND.122:A phase I/II pharmacokinetic and pharmacodynamic study of ZD1839 (‘Iressa’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients with colorectal cancer. Eur J Cancer 2001;37:s289.
Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Yoshimura N, Takeda K, Tanigawara Y, Swaisland H: Final results of a phase I intermittent dose-escalation trial of ZD1839 (‘Iressa’) in Japanese patients with various solid tumours (abstract 1292). Proc Am Soc Clin Oncol 2001;20:324a.
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110–124.
Goss G, Stewart D, Hirte H, Miller WH, Major P, Batist G, Matthews S, Douglas L, Lorimer L, Seymour L: Initial results of part 2 of a phase I/II pharmacokinetic, pharmacodynamic and biological activity study of ZD1839 (‘Iressa’): NCIC CTG IND.122 (abstract 59). Proc Am Soc Clin Oncol 2002;21:16a.
Cohen EE, Rosen F, Dekker A, Bajda C, Stenson K, Shulman KL, Lamont E, Kozloff M, Vokes EE: Phase II study of ZD1839 (‘Iressa’) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (abstract 899). Proc Am Soc Clin Oncol 2002;21:225a.
Drucker BJ, Schwartz L, Marion S, Motzer R: Phase II trial of ZD1839 (‘Iressa’), an EGF receptor inhibitor, in patients with advanced renal cancer (abstract 720). Proc Am Soc Clin Oncol 2002;21:181a.
Fukouka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste JF, Kudou S, Averbuch S, Macleod A, Feyereislova A, Baselga J: Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small cell lung cancer (IDEAL 1) (abstract 1188). Proc Am Soc Clin Oncol 2002;21:298a.
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A: A phase II trial of ZD1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) (abstract 1166). Proc Am Soc Clin Oncol 2002;21:292a.
Douillard J-Y, Giaccone G, Horai T, Noda K, Vansteenkiste JF, Takata I, Gatzemeier U, Fukuoka M, Macleod A, Feyereislove A, Averbuch S, Nogi Y, Heyes A, Baselga J: Improvement in diease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (‘Iressa’) (IDEAL 1) (abstract 1195). Proc Am Soc Clin Oncol 2002;21:299a.
Natale RB, Skarin AT, Maddox A-M, Hammond L, Thomas R, Gandara DR, Gerstein H, Panella TJ, Cole J, Jahanzeb M, Kash J, Hamm J, Langer CJ, Saleh M, Stella PJ, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A: Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (‘Iressa’) in IDEAL 2 (abstract 1167). Proc Am Soc Clin Oncol 2002;21:292a.
Janne PA, Ostler PA, Lucca J, Fidias P, Skarin AT, Lynch TL, Johnson BE: ZD1839 (‘Iressa’) shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol (abstract 1274). Proc Am Soc Clin Oncol 2002;21:319a.
Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Rocha Lima C, Ettienne K, Vaughn J, Belper G, Lee H: ZD1839 (‘Iressa’) as a single agent for the treatment of metastatic non-small lung cancer (abstract 1269). Proc Am Soc Clin Oncol 2002;21:318a.
Liem AK, Cheng H, Quan E, Ucar K, Al-Jazayrly G, Barton C, Cloo L, Gabert T, Tchekmedyian S: Expanded access single institution clinical program experience with ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (NSCLC) (abstract 2705). Proc Am Soc Clin Oncol 2002;21:222b.
Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885–4892.
Gonzalez-Larriba JL, Giaccone G, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJF, Smith R, Fandi A, Averbuch S: ZD1839 (‘Iressa’) in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial (abstract 376). Proc Am Soc Clin Oncol 2002;21:95a.
Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, Kris MG, Ochs J, Averbuch S: A pilot trial demonstrates the safety of ZD1839 (‘Iressa’), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC) (abstract 1301). Proc Am Soc Clin Oncol 2001;20:326a.
Hammond LA, Figueroa J, Schwartzberg L, Ochoa L, Hidalgo M, Olivo N, Schwartz G, Smith L, Ochs J, Rowinsky EK: ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitior, in combination with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer (abstract 549). Proc AACR-NCI-EORTC 2001.
Greenberger LM, Discafani C, Wang Y-F, Tsou H-R, Overbeek EG, Nilakantan R, Frost P, Wissner A: EKB-569: a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer. (abstract 388). Proc NCI-EORTC-AACR 2000.
Hidalgo M, Erlichman C, Rowinsky E, Koepp-Norris J, Jensen K, Boni J, Korth Bradley J, Quinn S, Zacharchuk C: Phase 1 trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors (abstract 65). Proc Am Soc Clin Oncol 2002;21:17a.
Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ: Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926–2935.
Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ: Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001;7:2563–2572.
Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL: A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI-166, a novel tyrosine kinase inhibitor, in patients with advanced cancers (abstract 377). Proc Am Soc Clin Oncol 2002;21:95a.
Hoekstra R, Dumez H, Eskens FALM, Sizer K, Cohen P, Ravera C, Verweij J, van Oosterom AT: A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, administered orally to patients with advanced cancer (abstract 585). Proc AACR-NCI-EORTC 2001.
Hoekstra R, Dumez H, van Oosterom AT, Sizer KC, Ravera C, Vaidyanathan S, Verweij J, Eskens FA: A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer (abstract 340). Proc Am Soc Clin Oncol 2002;21:86a.
Dumez H, Hoekstra R, Eskens F, Sizer K, Vaidyanathan S, Ravera C, van Oosterom A, Verweij J: A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer (abstract 341). Proc Am Soc Clin Oncol 2002;21:86a.
Rusnak DW, Affleck K, Gilmer TM, Jowett A, Lackey K, Spector N, Xia W: The effects of the novel EGFR/ErbB-2 tyrosine kinase inhibitor, Gw2016, on the growth of human normal and transformed cell lines (abstract 4309). Proc Am Assoc Cancer Res 2001;42:803.
Keith BR, Allen PP, Alligood KJ, Crosby RM, Lackey K, Gilmer TM, Mullin RJ: Anti tumor activity of GW2016 on the ErbB-2 positive human breast cancer xenograft, BT474 (abstract 4308). Proc Am Assoc Cancer Res 2001;42:803.
Mullin RJ, Alligood KJ, Allen PP, Crosby RM, Keith BR, Lackey K, Gilmer TM, Griffin RJ, Murray DM, Tadepalli SM: Antitumor activity of GW2016 in the EGFR positive human head and neck cancer xenograft, HN5 (abstract 4579). Proc Am Assoc Cancer Res 2001;42:854.
DeSimone PA, Bence AK, Anderson EB, Halepota MA, Smith DA, Koch KM, Stead AG, Mangum SG, Spector NL, Davis GA, Doukas MA, Adams VR: A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers (abstract 375). Proc Am Soc Clin Oncol 2002;21:94a.
Adams VR, Bence AK, Anderson EB, Halepota MA, Smith DA, Koch KM, Bowen CJ, Mangum SG, Spector NL, Davis GA, Doukas MA, DeSimone PA: A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects (abstract 374). Proc Am Soc Clin Oncol 2002;21:94a.
Gieseg MA, de Bock C, Ferguson LR, Denny WA: Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001;12:681–682.
Slichenmyer WJ, Elliott WL, Fry DW: CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001;28:80–85.
Breider MA: Irreversible inhibition of ErbB receptor family in rats results in epithelial atrophy and ulcerative dermatitis (abstract 3142). Proc Am Assoc Cancer Res 2000;41:493.
Zinner RG, Nemunaitis JJ, Donato NJ, Shin HC, Meyers JN, Zhang PS, Zentgraf RE, Khuri FR, Glisson BS, Eisman I, Olson SC, Bycott P, Lenehan PF, Wong WK, Shin DM: A phase I clinical and biomarker study of the novel pan-erbB tyrsine kinase inhibitor, CI-1033 (abstract 566). Proc AACR-NCI-EORTC 2001.
Rinehart JJ, Wilding G, Willson, Krishnamurthi S, Natale R, Mani S, Burnett D, Olson S, Bycott P, Owens-Grillo JK, Hes M, Lenehan P: A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors (abstract 41). Proc Am Soc Clin Oncol 2002;21:11a.
Garrison MA, Tolcher A, McCreery H, Rowinsky EK, Schott A, Mace J, Drengler R, Patnaik A, Denis L, Lenehan P, Eiseman I, Bycott P, Olson S, Baker L: A phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and every 15 every 28 days to patients with solid tumours (abstract 283). Proc Am Soc Clin Oncol 2001;20:72a.
Kunkel MW, Hook KE, Howard CT, Przybranowski S, Roberts BJ, Elliott WL, Leopold WR: Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs 1996;13:295–302.
Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM: Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022–12027.
Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL: Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chemother Pharmacol 2000;45:231–238.
Baselga J, Yano S, Giaccone G, Nakagawa K, Tamura T, Douillard J-Y, Nishiwaki Y, Vansteenkiste JF, Kudou S, Rischin D, Eek R, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Fukouka M: Initial results from a phase II trial of ZD1839 (‘Iressa’) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL1) (abstract 630A). Proc AACR-NCI-EORTC 2001.
Huang S, Li J, Harari PM: Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas (abstract 259). Proc AACR-NCI-EORTC 2001.
Raben D, Helfrich B, Chan D, Shogun T, Zundel W, Scafani R, Bunn P: The effects of ZD1839 on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitro (abstract 756). Proc AACR-NCI-EORTC 2001.
Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65–72.
Eiseman JL, Lagatutta TF, Joseph E, Hamburger DR, Covey JM, Parise RA, Egorin MJ: Plasma pharmacokinetics and tissue distribution in CD2F1 mice of the ErbB-2 selective kinase inhibitor, B17 (NSC71090), and its demethylated acid metabolite (abstract 4975). Proc Am Assoc Cancer Res 2002;43:1003–1004.
Naito K, Matsutani E, Tamura T, Miwa K, Takakura N, Asada M, Tasaka A, Miyake A, Terashita Z-I: TAK-165, a selective inhibitor of HER2 tyrosine kinase: 1. Nature of tyrosine kinase inhibition and selective antitumor activity in vivo and in vitro (abstract 3897). Proc Am Assoc Cancer Res 2002;43:786.
Rabindran SK, Discafani CM, Floyd MB, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Rosfjord E, Shen R, Shi S, Tsou H-R, Wang Y-F, Wissner A: Antitumor activity of compound 820 in xenografts: an orally active irreversible inhibitor of the HER-2 receptor tyrosine kinase (abstract 4965). Proc Am Assoc Cancer Res 2002;43:1001–1002.
Beckers TL, Reissmann T, Schmidt M, Weinberger H, Kutscher B, Strawn L, Wei J, McMahon G, Shawer L: SU11464/D-69491, a selective and potent pan HER tyrosine kinase inhibitor (abstract 3884). Proc Am Assoc Cancer Res 2002;43:784.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 